HALO
Halozyme Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$77.09-0.93%
Price as of Jul 20, 2026
HALO valuation
Halozyme Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 8.25x
- P/E 2026E
- 9.68x
- P/E 2027E
- 7.88x
- P/E 2028E
- 7.34x
- P/S forward
- 4.78x
Trailing multiples
- P/E TTM
- 26.40x
- PEG TTM
- 0.12x
- Price / book
- 41.63x
- Price / sales
- 6.06x
- Price / cash flow
- 13.50x
Enterprise value
- Enterprise value
- $11.0B
- EV / sales
- 7.27x
- EV / EBITDA
- 17.59x
- EV / EBIT
- 12.77x
- Market cap
- $9.1B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.